tirzepatide diabetes trial Tirzepatide Shows Superior Weight Loss Over Semaglutide in Phase 3 Trial

Tirzepatide cuts risk of diabetes by 94% in adults with prediabetes and obesity or overweight, drugmaker says

26.77

★★★★☆4.8 (126)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

22.58

★★★★★4.9 (98)

What Is Tirzepatide Used for? Approved and Potential Uses

27.50

★★★★★5.0 (157)

Tirzepatide Significantly Reduced A1C and Body Weight in People with Type 2 Diabetes in Two Phase 3 Trials from Lilly's SURPASS Program

24.45

★★★★★4.7 (84)

Effects of tirzepatide on adjudicated cardiovascular events in

23.35

★★★★★4.9 (203)

Semaglutide. Tirzepatide. The names dominate headlines: “Game-changing weight loss injections.” “A revolution in diabetes care.” But beyond the buzz, here's what the evidence says: Glycemic control: Landmark trials (SURPASS, SUSTAIN) show significant

27.39

★★★★★5.0 (176)

Can a weight loss and diabetes drug treat long COVID? – San Diego Union-Tribune

28.37

★★★★★4.8 (132)